Inhibikase Therapeutics, INC Form 4 insider transactions

Director Arvind Kush reports the acquisition of stock options in Inhibikase Therapeutics, Inc.

Director Roberto Bellini reports the acquisition of stock options in Inhibikase Therapeutics, Inc.

Director Roy Lester Freeman of Inhibikase Therapeutics, Inc. was granted stock options on February 14, 2025, according to a Form 4 filing with the SEC.

Director Amit Munshi reports acquisition of stock options in Inhibikase Therapeutics, Inc.

Director David Canner acquired stock options in Inhibikase Therapeutics, Inc. on February 14, 2025.

Dennis Berman, a director at Inhibikase Therapeutics, files an amended Form 4 to correct the reported beneficial owner of stock options.

Director Dennis Berman reports acquisition of stock options in Inhibikase Therapeutics.

Garth Lees-Rolfe, CFO of Inhibikase Therapeutics, reports repricing of stock options effective January 21, 2025.

Director Roy Lester Freeman adjusts his stock option holdings in Inhibikase Therapeutics following a board-approved and stockholder-ratified repricing event.

CEO Milton H. Werner reports adjustments to stock option holdings in Inhibikase Therapeutics following an option repricing approved by the board and stockholders.

Director Dennis N. Berman reports adjustments to stock options and acquisition of derivative securities in Inhibikase Therapeutics, Inc. following a reverse stock split and option repricing.

Inhibikase Therapeutics CEO, Milton H. Werner, was granted multiple tranches of stock options, exercisable at different prices, tied to the exercise of warrants.

Garth Lees-Rolfe, Chief Financial Officer of Inhibikase Therapeutics, acquired stock options with varying exercise prices, according to a recent SEC filing.

Roy Lester Freeman, a director at Inhibikase Therapeutics, acquired stock options with varying exercise prices and vesting conditions.

Director Dennis N. Berman acquired stock options for Inhibikase Therapeutics, Inc. on January 3, 2025, with varying exercise prices and vesting conditions.

Director David Canner acquired stock options for 60,000 shares of Inhibikase Therapeutics, Inc. at an exercise price of $2.22 on October 21, 2024.

Roberto Bellini, a director of Inhibikase Therapeutics, Inc., reports the acquisition of 1,460,000 shares of common stock and 60,000 stock options.

Director Arvind Kush purchased 145,000 shares of Inhibikase Therapeutics and acquired stock options for 60,000 shares on October 21, 2024.

Director Amit Munshi reports acquisition of Inhibikase Therapeutics shares and stock options.

Director Paul C. Grint acquired 30,000 stock options in Inhibikase Therapeutics, Inc. on July 16, 2024.

Gisele Dion, a director of Inhibikase Therapeutics, Inc., reported the acquisition of 30,000 stock options on July 16, 2024.

Director Dennis N. Berman acquired stock options for Inhibikase Therapeutics, Inc. on July 16, 2024.

Director Roy Lester Freeman acquired 30,000 stock options in Inhibikase Therapeutics, Inc. (IKT) on July 16, 2024.

Milton H. Werner, President and CEO of Inhibikase Therapeutics, Inc., reports the acquisition of 45,000 stock options on April 1, 2024.

Garth Lees-Rolfe, CFO of Inhibikase Therapeutics, acquired 90,000 stock options on April 1, 2024, according to a recent SEC filing.